MRK240816P117000
- 3.00
- -0.71-19.14%
Merck & Co Newsroom
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Investing in Merck (NYSE:MRK) Three Years Ago Would Have Delivered You a 63% Gain
Merck's Net Cash Will See It Through -- Barrons.com
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Merck (MRK.US) terminates Phase III study of PD-1+TIGIT combination therapy as first-line treatment for extensive-stage small cell lung cancer.
On August 8, Merck (MRK.US) announced that, following the recommendation of an independent data monitoring committee (DMC), the development of KeyVibe-008 in Phase III will be terminated.
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion
Merck Has Agreed To Acquire CN201, An Investigational Clinical-stage Bispecific Antibody For B-cell Associated Diseases, From A Privately Held Curon Biopharmaceutical For An Upfront Payment Of $700M In Cash And Up To $600M In Milestone Payments
Express News | Merck & Co Inc - to Update Financial Outlook in Q3 2024
Express News | Merck & Co Inc - Expects to Record a Pre-Tax Charge of Approximately $750 Mln
Express News | Merck & Co Inc - Curon Eligible for $600M Milestone Payments
Express News | Merck & Co Inc - Pays $700M Upfront for Cn201
Express News | Merck to Acquire Investigational B-Cell Depletion Therapy, Cn201, From Curon Biopharmaceutical
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Looking Into Merck & Co's Recent Short Interest
Merck Ends Trial Evaluating Lung Cancer Treatment Following Committee Recommendation
Merck Halts Phase 3 Trial of Lung Cancer Combination Therapy
Merck Lung Cancer Combo Therapy Fails in Phase 3 Trial
Merck Says It's Discontinuing a Late-stage Trial of a Lung Cancer Treatment After High Number of Adverse Events
Merck to Discontinue Phase 3 Lung Cancer Drug Trial on Committee's Recommendation